Taiko PharmaceuticalTAIKO PHARMACEUTICAL CO., LTD.4574東証プライム医薬品FY ending Dec 2025, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|---|
| Pharmaceuticals Business | +10.1%5y | 4,35033.9% | 3,6248.2% | 5,18523.4% | 5,77833.7% | 5,77127.3% |
| Infection Control Business | -46.4%5y | 6,942-71.1% | 1,408-154.8% | 929-128.3% | 508-91.9% | 619-41.0% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書-第80期(2025/01/01-2025/12/31)
EDINET (FSA Japan)
有価証券報告書-第79期(2024/01/01-2024/12/31)
EDINET (FSA Japan)
有価証券報告書-第78期(2023/01/01-2023/12/31)
EDINET (FSA Japan)
有価証券報告書-第77期(2022/01/01-2022/12/31)
EDINET (FSA Japan)
有価証券報告書-第76期(令和3年1月1日-令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書-第75期(令和2年4月1日-令和2年12月31日)
Extracted from XBRL: 46 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.